GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Pierre Stafrace retires as Farsons Imports General Manager and takes on new role
Pierre Stafrace will now work with Farsonsdirect’s private clients.
Michael Stivala: Cutting construction dissatisfaction to 25% ‘ambitious but achievable’
The Vision 2050 strategy envisages cutting the level of citizen dissatisfaction with construction from 70% to 25% by 2035.
Farsons names Alistair Martin Haber as Chief Digital and Technology Officer
He brings more than 25 years of international experience in digital transformation, infrastructure modernisation and cloud strategy across enterprise environments
Matthew Ellul Sullivan assesses how Middle East war could impact Malta
He said that Malta could be negatively impacted if the closure of the Strait of Hormuz results in fewer vessels ...
